[Studies on the predictors of response to immunosuppressive therapy in severe aplastic anemia patients]
- PMID: 19950609
[Studies on the predictors of response to immunosuppressive therapy in severe aplastic anemia patients]
Abstract
Objective: To assay the factors that may predict the response to immunosuppressive therapy (IST) in severe aplastic anemia patients.
Methods: The blood samples were collected from 37 patients diagnosed as severe aplastic anemia in West China Hospital of Sichuan University and West China Second Hospital of Sichuan University during February, 2006 to March, 2007. Twenty healthy blood donors were used as normal control. The plasma levels of IFN-gamma and IL-2 were measured by enzyme linked immunosorbent assay, and the gene phenotype of HLA-DRB1 * 15 and HLA-DRB1 * 1501 was analyzed by polymerase chain reaction with sequence specific primer. The expressions of CD55 and CD59 on the cellular membrane of red blood cell and white blood cells also were measured.
Results: The response rate in the patients who had higher IL-2 level before IST was significantly better than that in the patients with lower IL-2 level (66.7% vs 28.6%, P<0.05), while similar result was observed to IFN-gamma (73.7% vs 25.0%, P<0.05). The response rate in the patients with positive HLA-DRB1 * 15 was higher than that in those negative patients (62.5% vs 44.4%, P>0.05), but there was no different found in different HLA-DRB1 * 1501 phenotypes (50% vs 50%, P>0.05). The response rates in the patients with deficient CD55 and CD59 expression were higher than those expressed CD55 and CD59 normally (80.0% vs 40.0%, P>0.05); the response rate of patients younger than 40 years was higher than those older than 40 years (60.0% vs 14.3%, P<0.05); the response rate in female patients was higher than male patients (62.5% vs 42.9%, P<0.05).
Conclusion: The concentration of IL-2, IFN-gamma before IST, and age can be used as the predicting factors to immunosuppressive therapy, while the predicting value of HLA-DRB1 * 15, HLA- DRB1 * 1501 and CD55, CD59 to the response of IST still remain unclear.
Similar articles
-
Association of the interferon-gamma single nucleotide polymorphism +874(T/A) with response to immunosuppressive therapy in patients with severe aplastic anemia.Blood Cells Mol Dis. 2010 Dec 15;45(4):313-6. doi: 10.1016/j.bcmd.2010.09.003. Epub 2010 Oct 12. Blood Cells Mol Dis. 2010. PMID: 20934357
-
Roles of DRB1 *1501 and DRB1 *1502 in the pathogenesis of aplastic anemia.Exp Hematol. 2007 Jan;35(1):13-20. doi: 10.1016/j.exphem.2006.09.002. Exp Hematol. 2007. PMID: 17198869
-
[Clinical implications of combined measurement bone marrow T cells intracellular IFNgamma and HLA-DRB1*1501 measurement in predicting the response to immunosuppressive therapy for aplastic anemia].Zhonghua Nei Ke Za Zhi. 2007 Oct;46(10):846-9. Zhonghua Nei Ke Za Zhi. 2007. PMID: 18218241 Chinese.
-
Treatment of aplastic anaemia in elderly patients aged >60 years.Bone Marrow Transplant. 2013 Feb;48(2):180-2. doi: 10.1038/bmt.2012.224. Epub 2012 Nov 26. Bone Marrow Transplant. 2013. PMID: 23178542 Review.
-
[Role of antigen-specific T cells in the pathogenesis of aplastic anemia].Rinsho Ketsueki. 1999 Mar;40(3):159-63. Rinsho Ketsueki. 1999. PMID: 10222616 Review. Japanese. No abstract available.
Cited by
-
Association of Human Leukocyte Antigen DRB1*15 and DRB1*15:01 Polymorphisms with Response to Immunosuppressive Therapy in Patients with Aplastic Anemia: A Meta-Analysis.PLoS One. 2016 Sep 9;11(9):e0162382. doi: 10.1371/journal.pone.0162382. eCollection 2016. PLoS One. 2016. PMID: 27611583 Free PMC article.
-
[The current status and development of haploidentical allogeneic hematopoietic stem cell transplantation for severe aplastic anemia].Zhonghua Xue Ye Xue Za Zhi. 2015 Aug;36(8):707-10. doi: 10.3760/cma.j.issn.0253-2727.2015.08.019. Zhonghua Xue Ye Xue Za Zhi. 2015. PMID: 26462647 Free PMC article. Chinese. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous